ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

OPTI Optibiotix Health Plc

19.60
-1.40 (-6.67%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Optibiotix Health Plc LSE:OPTI London Ordinary Share GB00BP0RTP38 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.40 -6.67% 19.60 20.00 20.50 21.50 20.25 21.00 572,429 16:35:01
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Noncomml Resh Organizations 457k 2.59M 0.0284 7.13 18.47M

OptiBiotix Health PLC Transfer of certain SkinBioTherapeutics plc shares (0909H)

29/07/2019 4:03pm

UK Regulatory


Optibiotix Health (LSE:OPTI)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Optibiotix Health Charts.

TIDMOPTI

RNS Number : 0909H

OptiBiotix Health PLC

29 July 2019

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Transfer of certain SkinBioTherapeutics plc shares

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that a portion of its shareholding in SkinBioTherapeutics plc consisting of 20,438,496 ordinary shares representing 15.88% of SkinBioTherapeutics plc's total issued share capital, have been dematerialised and transferred to a nominee CREST account (Pershing Nominees). OptiBiotix plc remains the beneficial owner of the transferred 20,438,496 ordinary shares.

There has been no change in the Company's overall beneficial holding of its SkinBioTherapeutics plc shareholding which in total consists of 49,794,190 representing 38.9% of SkinBioTherapeutics plc's total issued share capital.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

 
 OptiBiotix Health plc                                  www.optibiotix.com 
 Stephen O'Hara, Chief Executive                      Contact via Walbrook 
                                                                     below 
 
 Cairn Financial Advisers LLP (NOMAD) 
 Liam Murray / Jo Turner / Ludovico Lazzaretti          Tel: 020 7213 0880 
 
   finnCap (Broker) 
 Geoff Nash / Kate Bannatyne (Corporate Finance) 
                                                        Tel: 020 7220 0500 
 Camille Gochez (Corporate Broking) 
 
 goetzpartners securities Limited                       Tel: 0203 859 7725 
 Ulrich Kinzel 
 
 Walbrook PR Ltd 
 Anna Dunphy                                            Mob: 07876 741 001 
 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCGMGZNKLMGLZM

(END) Dow Jones Newswires

July 29, 2019 11:03 ET (15:03 GMT)

1 Year Optibiotix Health Chart

1 Year Optibiotix Health Chart

1 Month Optibiotix Health Chart

1 Month Optibiotix Health Chart

Your Recent History

Delayed Upgrade Clock